Formycon AG (DE:FYB)
XETRA:FYB
Want to see DE:FYB full AI Analyst Report?
FYB Stock Chart & Stats
€19.82
€0.60(0.99%)
At close: 4:00 PM EST
€19.82
€0.60(0.99%)
Day’s Range― - ―
52-Week Range€15.80 - €31.30
Previous CloseN/A
Volume3.47K
Average Volume (3M)24.96K
Market Cap
€315.99M
Enterprise Value€256.71M
Total Cash (Recent Filing)€68.85M
Total Debt (Recent Filing)€9.56M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding17,672,928
10 Day Avg. Volume17,772
30 Day Avg. Volume24,962
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.13
Price to Sales (P/S)10.17
P/FCF Ratio-10.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€34.50Price Target Upside74.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.22
Revenue Forecast (FY)€91.90M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and a well-capitalized balance sheet provide durable financial flexibility for a development-stage biotech. This helps absorb development delays, fund clinical programs, and negotiate partnerships without immediate refinancing pressure, supporting multi-quarter strategic execution.
Improved Operating Cash FlowA shift to positive operating cash flow signals improving underlying cash generation from core activities, reducing reliance on financing for day-to-day operations. Over 2–6 months this increases runway and credibility with partners and creditors while investments persist.
Partner-driven Commercial ModelRelying on partners for commercialization limits the need for a large in-house sales footprint and capex. Milestones, licensing and profit-share structures can de-risk cash outlays and accelerate market access, making the business model scalable and capital-efficient over time.
Bears Say
Revenue Contraction & VolatilitySustained revenue declines and volatility undermine predictable milestone timing and future royalty streams. For a partner-dependent biosimilars developer, weaker top-line trends reduce bargaining power on deals and delay cash receipts tied to approvals and commercial uptake.
Deep Negative Free Cash FlowPersistently negative free cash flow indicates current operations and investments are not self-financing. Over several quarters this elevates funding risk, potentially forcing dilutive equity raises or debt, and strains the balance sheet despite currently low leverage.
Inconsistent ProfitabilityLarge swings from profit to deep loss reduce forecasting reliability and can erode equity and partner confidence. Inconsistent earnings complicate long-term planning, increase perceived execution risk, and may worsen terms on future collaborations or financing.
Formycon AG News
FYB FAQ
What was Formycon AG’s price range in the past 12 months?
Formycon AG lowest stock price was €15.80 and its highest was €31.30 in the past 12 months.
What is Formycon AG’s market cap?
Formycon AG’s market cap is €315.99M.
When is Formycon AG’s upcoming earnings report date?
Formycon AG’s upcoming earnings report date is Jul 01, 2026 which is in 61 days.
How were Formycon AG’s earnings last quarter?
Formycon AG released its earnings results on Apr 22, 2026. The company reported -€0.59 earnings per share for the quarter, missing the consensus estimate of -€0.19 by -€0.4.
Is Formycon AG overvalued?
According to Wall Street analysts Formycon AG’s price is currently Undervalued.
Does Formycon AG pay dividends?
Formycon AG does not currently pay dividends.
What is Formycon AG’s EPS estimate?
Formycon AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Formycon AG have?
Formycon AG has 17,672,928 shares outstanding.
What happened to Formycon AG’s price movement after its last earnings report?
Formycon AG reported an EPS of -€0.59 in its last earnings report, missing expectations of -€0.19. Following the earnings report the stock price went down -3.987%.
Which hedge fund is a major shareholder of Formycon AG?
Currently, no hedge funds are holding shares in DE:FYB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Formycon AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.19%
12-Months-Change
Fundamentals
Return on Equity
-16.02%
Trailing 12-Months
Asset Growth
-4.17%
Trailing 12-Months
Company Description
Formycon AG
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
FYB Stock 12 Month Forecast
Average Price Target
€34.50
▲(74.07% Upside)
Technical Analysis
Options Prices
Currently, No data available
---